Penalty For Daiichi As It Falls Short In Japan Flu Vaccine Project
Executive Summary
Japanese firm fails to meet production capacity target under Japan national flu vaccine supply plan, triggering a financial penalty and the return of government grant money.
You may also be interested in...
Boost For Daiichi's Oncology Ambitions As AZ Agrees Huge $6.9bn Deal For Lead ADC Asset
AstraZeneca is paying $1.35bn upfront for global rights to a flagship Daiichi Sankyo oncology asset, in a deal potentially worth up to $6.9bn set to give a huge boost to the Japanese firm's ambitions in the sector.
Daiichi Sankyo Hauls Back Mid-Term Profit Outlook As It Builds Oncology
Big cut in mid-term profit outlook hits Daiichi Sankyo shares but company says it is reallocating more to R&D to accelerate the strategic build-out of its oncology franchise.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.